{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:22:13Z","timestamp":1753888933081,"version":"3.41.2"},"reference-count":31,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,30]]},"DOI":"10.20945\/2359-4292-2023-0311","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T21:02:34Z","timestamp":1722546154000},"source":"Crossref","is-referenced-by-count":0,"title":["Budget impact analysis of cabergoline for medical treatment of Cushing\u2019s disease in Brazil"],"prefix":"10.20945","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5454-9433","authenticated-orcid":false,"given":"Lukas Fernando de Oliveira","family":"Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4832-7294","authenticated-orcid":false,"given":"Julia Sim\u00f5es Corr\u00eaa","family":"Galendi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7272-9552","authenticated-orcid":false,"given":"Manoel Ricardo Alves","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9316-4167","authenticated-orcid":false,"given":"Vania dos Santos Nunes","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8510","reference":[{"key":"key20240801170200_B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000314297","article-title":"Epidemiology of Cushing's syndrome","volume":"92","author":"Steffensen","year":"2010","unstructured":"1. Steffensen C, Bak AM, Rubeck KZ, J\u00f8rgensen JO. Epidemiology of Cushing's syndrome. Neuroendocrinology. 2010;92 Suppl 1:1-5. doi: 10.1159\/000314297.","journal-title":"Neuroendocrinology"},{"issue":"5","key":"key20240801170200_B2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrendo.2011.12","article-title":"Management of Cushing disease","volume":"7","author":"Tritos","year":"2011","unstructured":"2. Tritos NA, Biller BM, Swearingen B. Management of Cushing disease. Nat Rev Endocrinol. 2011 May;7(5):279-89. doi: 10.1038\/nrendo.2011.12.","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"key20240801170200_B3","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1210\/jc.2006-2112","article-title":"Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma","volume":"92","author":"Dekkers","year":"2007","unstructured":"3. Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH, et al. Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab. 2007 Mar;92(3):976-81. doi: 10.1210\/jc.2006-2112.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"key20240801170200_B4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2265.1994.tb02486.x","article-title":"Morbidity and mortality in Cushing's disease: an epidemiological approach","volume":"40","author":"Etxabe","year":"1994","unstructured":"4. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994 Apr;40(4):479-84. doi: 10.1111\/j.1365-2265.1994.tb02486.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"key20240801170200_B5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ejim.2011.10.013","article-title":"Mortality in Cushing's syndrome: a systematic review and meta-analysis","volume":"23","author":"Graversen","year":"2012","unstructured":"5. Graversen D, Vestergaard P, Stochholm K, Gravholt CH, J\u00f8rgensen JO. Mortality in Cushing's syndrome: a systematic review and meta-analysis. Eur J Intern Med. 2012 Apr;23(3):278-82. doi: 10.1016\/j.ejim.2011.10.013.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"key20240801170200_B6","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1210\/jc.2012-2893","article-title":"Predictors of mortality and long-term outcomes in treated Cushing's disease: a study of 346 patients","volume":"98","author":"Lambert","year":"2013","unstructured":"6. Lambert JK, Goldberg L, Fayngold S, Kostadinov J, Post KD, Geer EB. Predictors of mortality and long-term outcomes in treated Cushing's disease: a study of 346 patients. J Clin Endocrinol Metab. 2013 Mar;98(3):1022-30. doi: 10.1210\/jc.2012-2893.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"key20240801170200_B7","doi-asserted-by":"crossref","first-page":"R227","DOI":"10.1530\/EJE-14-0883","article-title":"Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence","volume":"172","author":"Petersenn","year":"2015","unstructured":"7. Petersenn S, Beckers A, Ferone D, van der Lely A, Bollerslev J, Boscaro M, et al. Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. Eur J Endocrinol. 2015 Jun;172(6):R227-39. doi: 10.1530\/eje-14-0883.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"key20240801170200_B8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1530\/EJE-12-0921","article-title":"Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study","volume":"168","author":"Alexandraki","year":"2013","unstructured":"8. Alexandraki KI, Kaltsas GA, Isidori AM, Storr HL, Afshar F, Sabin I, et al. Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study. Eur J Endocrinol. 2013 Mar 20;168(4):639-48. doi: 10.1530\/eje-12-0921.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"key20240801170200_B9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/02688690400012459a","article-title":"Complications after trans-sphenoidal surgery: our experience and a review of the literature","volume":"18","author":"Sudhakar","year":"2004","unstructured":"9. Sudhakar N, Ray A, Vafidis JA. Complications after trans-sphenoidal surgery: our experience and a review of the literature. Br J Neurosurg. 2004 Oct;18(5):507-12. doi: 10.1080\/02688690400012459a.","journal-title":"Br J Neurosurg"},{"issue":"2","key":"key20240801170200_B10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1530\/EJE-14-0214","article-title":"Favorable long-term outcomes of bilateral adrenalectomy in Cushing's disease","volume":"171","author":"O\u00dfwald","year":"2014","unstructured":"10. O\u00dfwald A, Plomer E, Dimopoulou C, Milian M, Blaser R, Ritzel K, et al. Favorable long-term outcomes of bilateral adrenalectomy in Cushing's disease. Eur J Endocrinol. 2014 Aug;171(2):209-15. doi: 10.1530\/eje-14-0214.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"key20240801170200_B11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11102-018-0897-z","article-title":"Effectiveness of medical treatment for Cushing's syndrome: a systematic review and meta-analysis","volume":"21","author":"Broersen","year":"2018","unstructured":"11. Broersen LHA, Jha M, Biermasz NR, Pereira AM, Dekkers OM. Effectiveness of medical treatment for Cushing's syndrome: a systematic review and meta-analysis. Pituitary. 2018 Dec;21(6):631-41. doi: 10.1007\/s11102-018-0897-z.","journal-title":"Pituitary"},{"issue":"6","key":"key20240801170200_B12","doi-asserted-by":"crossref","first-page":"968","DOI":"10.4158\/EP10031.OR","article-title":"Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy","volume":"16","author":"Lila","year":"2010","unstructured":"12. Lila AR, Gopal RA, Acharya SV, George J, Sarathi V, Bandgar T, et al. Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. Endocr Pract. 2010 Nov-Dec;16(6):968-76. doi:10.4158\/ep10031.OR.","journal-title":"Endocr Pract"},{"issue":"5","key":"key20240801170200_B13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1530\/EJE-10-0382","article-title":"Cabergoline monotherapy in the long-term treatment of Cushing's disease","volume":"163","author":"Godbout","year":"2010","unstructured":"13. Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol. 2010 Nov;163(5):709-16. doi: 10.1530\/eje-10-0382.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"key20240801170200_B14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1530\/EJE-16-0662","article-title":"Cabergoline for Cushing's disease: a large retrospective multicenter study","volume":"176","author":"Ferriere","year":"2017","unstructured":"14. Ferriere A, Cortet C, Chanson P, Delemer B, Caron P, Chabre O, et al. Cabergoline for Cushing's disease: a large retrospective multicenter study. Eur J Endocrinol. 2017 Mar;176(3):305-14. doi: 10.1530\/eje-16-0662.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"key20240801170200_B15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","article-title":"Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease","volume":"13","author":"Vilar","year":"2010","unstructured":"15. Vilar L, Naves LA, Azevedo MF, Arruda MJ, Arahata CM, Moura E Silva L, et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. Pituitary. 2010 Jun;13(2):123-9. doi: 10.1007\/s11102-009-0209-8.","journal-title":"Pituitary"},{"issue":"1","key":"key20240801170200_B16","first-page":"73","article-title":"Review and proposal to update the methodological guideline for budget impact analysis of health technology for the SUS","volume":"11","author":"Costa","year":"2019","unstructured":"16. Costa MGS, Luna LC, Leite PHAC, Tura BR, Pinto M, Santos M. Review and proposal to update the methodological guideline for budget impact analysis of health technology for the SUS. J Bras Econ Saude. 2019;11(1):73-86. doi: 10.21115\/JBES.v11.n1.p73-86.","journal-title":"J Bras Econ Saude"},{"journal-title":"An\u00e1lises de impacto or\u00e7ament\u00e1rio: manual para o Sistema de Sa\u00fade do Brasil","author":"Secretaria de Ci\u00eancia Tecnologia e Insumos Estrat\u00e9gicos","key":"key20240801170200_B17","unstructured":"17. Secretaria de Ci\u00eancia Tecnologia e Insumos Estrat\u00e9gicos. Departamento de Ci\u00eancia e Tecnologia. An\u00e1lises de impacto or\u00e7ament\u00e1rio: manual para o Sistema de Sa\u00fade do Brasil Availabe from: https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/diretrizes_metodologicas_analise_impacto.pdf. Accessed on: Jun 12, 2023."},{"issue":"5","key":"key20240801170200_B18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1524-4733.2007.00187.x","article-title":"Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis","volume":"10","author":"Mauskopf","year":"2007","unstructured":"18. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health. 2007 Sep-Oct;10(5):336-47. doi: 10.1111\/j.1524-4733.2007.00187.x.","journal-title":"Value Health"},{"key":"key20240801170200_B19","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.732240","article-title":"Effectiveness of Medical Treatment of Cushing's Disease: A Systematic Review and Meta-Analysis","volume":"12","author":"Sim\u00f5es Corr\u00eaa Galendi","year":"2021","unstructured":"19. Sim\u00f5es Corr\u00eaa Galendi J, Correa Neto ANS, Demetres M, Boguszewski CL, Nogueira VDSN. Effectiveness of Medical Treatment of Cushing's Disease: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2021 Sep 17;12:732240. doi: 10.3389\/fendo.2021.732240.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"key20240801170200_B20","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s40618-022-01754-1","article-title":"Global Cushing's disease epidemiology: a systematic review and meta-analysis of observational studies","volume":"45","author":"Giuffrida","year":"2022","unstructured":"20. Giuffrida G, Crisafulli S, Ferra\u00f9 F, Fontana A, Alessi Y, Calapai F, et al. Global Cushing's disease epidemiology: a systematic review and meta-analysis of observational studies. J Endocrinol Invest. 2022 Jun;45(6):1235-46. doi: 10.1007\/s40618-022-01754-1.","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"key20240801170200_B21","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101382","article-title":"Cushing's syndrome - Disease monitoring: Recurrence, surveillance with biomarkers or imaging studies","volume":"34","author":"Ragnarsson","year":"2020","unstructured":"21. Ragnarsson, O. Cushing's syndrome - Disease monitoring: Recurrence, surveillance with biomarkers or imaging studies. Best Pract Res Clin Endocrinol Metab. 2020;34(2):101382. doi: 10.1016\/j.beem.2020.101382.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"key20240801170200_B22","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s11102-018-0893-3","article-title":"Endoscopic vs. microscopic transsphenoidal surgery for Cushing's disease: a systematic review and meta-analysis","volume":"21","author":"Broersen","year":"2018","unstructured":"22. Broersen LHA, Biermasz NR, van Furth WR, de Vries F, Verstegen MJT, Dekkers OM, et al. Endoscopic vs. microscopic transsphenoidal surgery for Cushing's disease: a systematic review and meta-analysis. Pituitary. 2018 Oct;21(5):524-34. doi: 10.1007\/s11102-018-0893-3.","journal-title":"Pituitary"},{"issue":"1","key":"key20240801170200_B23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3171\/JNS\/2008\/108\/01\/0009","article-title":"Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years","volume":"108","author":"Hofmann","year":"2008","unstructured":"23. Hofmann BM, Hlavac M, Martinez R, Buchfelder M, M\u00fcller OA, Fahlbusch R. Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. J Neurosurg. 2008 Jan;108(1):9-18. doi: 10.3171\/jns\/2008\/108\/01\/0009.","journal-title":"J Neurosurg"},{"issue":"2","key":"key20240801170200_B24","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1210\/jc.2007-2013","article-title":"Late recurrences of Cushing's disease after initial successful transsphenoidal surgery","volume":"93","author":"Patil","year":"2008","unstructured":"24. Patil CG, Prevedello DM, Lad SP, Vance ML, Thorner MO, Katznelson L, et al. Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab. 2008 Feb;93(2):358-62. doi: 10.1210\/jc.2007-2013.","journal-title":"J Clin Endocrinol Metab"},{"author":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa)","key":"key20240801170200_B25","unstructured":"25. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa). C\u00e2mara de Regula\u00e7\u00e3o do Mercado de Medicamentos - CMED. Availabe from: http:\/\/portal.anvisa.gov.br\/cmed. Accessed on: 2023."},{"issue":"2","key":"key20240801170200_B26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11102-013-0475-3","article-title":"Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?","volume":"17","author":"Barbot","year":"2014","unstructured":"26. Barbot M, Albiger N, Ceccato F, Zilio M, Frigo AC, Denaro L, et al. Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole? Pituitary. 2014 Apr;17(2):109-17. doi: 10.1007\/s11102-013-0475-3.","journal-title":"Pituitary"},{"key":"key20240801170200_B27","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1145775","article-title":"Ketoconazole as second-line treatment for Cushing's disease after transsphenoidal surgery: systematic review and meta-analysis","volume":"14","author":"Viecceli","year":"2023","unstructured":"27. Viecceli C, Mattos ACV, Hirakata VN, Garcia SP, Rodrigues TDC, Czepielewski MA. Ketoconazole as second-line treatment for Cushing's disease after transsphenoidal surgery: systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023 May 8;14:1145775. doi: 10.3389\/fendo.2023.1145775.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"key20240801170200_B28","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s40618-018-0936-7","article-title":"Effect of cabergoline monotherapy in Cushing's disease: an individual participant data meta-analysis","volume":"41","author":"Palui","year":"2018","unstructured":"28. Palui R, Sahoo J, Kamalanathan S, Kar SS, Selvarajan S, Durgia H. Effect of cabergoline monotherapy in Cushing's disease: an individual participant data meta-analysis. J Endocrinol Invest. 2018 Dec;41(12):1445. doi: 10.1007\/s40618-018-0936-7.","journal-title":"J Endocrinol Invest"},{"key":"key20240801170200_B29","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1016\/j.jval.2018.04.1694","article-title":"Budget Impact of Pasireotide Lar for the Treatment of Cushing's Disease from a Finnish Societal Perspective","volume":"21","author":"Lee","year":"2018","unstructured":"29. Lee KW, Niskanen L, Olson F, Bornheimer R, Maamari R, Neary MP. Budget Impact of Pasireotide Lar for the Treatment of Cushing's Disease from a Finnish Societal Perspective. Value Health. 2018;21:S250-1. doi: https:\/\/doi.org\/10.1016\/j.jval.2018.04.1694.","journal-title":"Value Health"},{"issue":"4","key":"key20240801170200_B30","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3111\/13696998.2013.877470","article-title":"Budget impact of pasireotide for the treatment of Cushing's disease, a rare endocrine disorder associated with considerable comorbidities","volume":"17","author":"Truong","year":"2014","unstructured":"30. Truong HL, Nellesen D, Ludlam WH, Neary MP. Budget impact of pasireotide for the treatment of Cushing's disease, a rare endocrine disorder associated with considerable comorbidities. J Med Econ. 2014 Apr;17(4):288-95. doi:10.3111\/13696998.2013.877470.","journal-title":"J Med Econ"},{"issue":"9","key":"key20240801170200_B31","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","unstructured":"31. Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, et al. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol. 2020 Sep;8(9):748-61. doi:10.1016\/s2213-8587(20)30240-0.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T21:02:54Z","timestamp":1722546174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/budget-impact-analysis-of-cabergoline-for-medical-treatment-of-cushings-disease-in-brazil\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":31,"alternative-id":["10.20945\/2359-4292-2023-0311"],"URL":"https:\/\/doi.org\/10.20945\/2359-4292-2023-0311","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"type":"print","value":"2359-3997"},{"type":"electronic","value":"2359-4292"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e230311"}}